261 related articles for article (PubMed ID: 22421945)
1. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
2. A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
Oba T; Hoki T; Yamauchi T; Keler T; Marsh HC; Cao X; Ito F
J Immunol; 2020 Oct; 205(7):1867-1877. PubMed ID: 32848036
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
Lou Y; Wang G; Lizée G; Kim GJ; Finkelstein SE; Feng C; Restifo NP; Hwu P
Cancer Res; 2004 Sep; 64(18):6783-90. PubMed ID: 15374997
[TBL] [Abstract][Full Text] [Related]
4. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW
Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424
[TBL] [Abstract][Full Text] [Related]
6. CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells.
Hu HM; Winter H; Ma J; Croft M; Urba WJ; Fox BA
J Immunol; 2002 Nov; 169(9):4897-904. PubMed ID: 12391201
[TBL] [Abstract][Full Text] [Related]
7. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
8. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.
Johnson EE; Buhtoiarov IN; Baldeshwiler MJ; Felder MA; Van Rooijen N; Sondel PM; Rakhmilevich AL
J Immunother; 2011 Jan; 34(1):76-84. PubMed ID: 21150715
[TBL] [Abstract][Full Text] [Related]
9. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
[TBL] [Abstract][Full Text] [Related]
10. CD86 (B7-2) on human B cells. A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells.
Jeannin P; Delneste Y; Lecoanet-Henchoz S; Gauchat JF; Ellis J; Bonnefoy JY
J Biol Chem; 1997 Jun; 272(25):15613-9. PubMed ID: 9188449
[TBL] [Abstract][Full Text] [Related]
11. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells.
Nakae S; Asano M; Horai R; Sakaguchi N; Iwakura Y
J Immunol; 2001 Jul; 167(1):90-7. PubMed ID: 11418636
[TBL] [Abstract][Full Text] [Related]
12. Murine Fibroblastic Reticular Cells From Lymph Node Interact With CD4+ T Cells Through CD40-CD40L.
Nakayama Y; Brinkman CC; Bromberg JS
Transplantation; 2015 Aug; 99(8):1561-7. PubMed ID: 25856408
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.
Hayakawa Y; Takeda K; Yagita H; Van Kaer L; Saiki I; Okumura K
J Immunol; 2001 May; 166(10):6012-8. PubMed ID: 11342617
[TBL] [Abstract][Full Text] [Related]
14. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
[TBL] [Abstract][Full Text] [Related]
15. Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors.
Donepudi M; Quach DD; Mokyr MB
Cancer Immunol Immunother; 1999; 48(2-3):153-64. PubMed ID: 10414470
[TBL] [Abstract][Full Text] [Related]
16. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
17. Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness.
Koenen HJ; Joosten I
Blood; 2000 May; 95(10):3153-61. PubMed ID: 10807782
[TBL] [Abstract][Full Text] [Related]
18. Expression of costimulatory molecule CD40 in murine heart with acute myocarditis and reduction of inflammation by treatment with anti-CD40L/B7-1 monoclonal antibodies.
Seko Y; Takahashi N; Azuma M; Yagita H; Okumura K; Yazaki Y
Circ Res; 1998 Aug; 83(4):463-9. PubMed ID: 9721703
[TBL] [Abstract][Full Text] [Related]
19. Rapid induction of a novel costimulatory activity on B cells by CD40 ligand.
Wu Y; Xu J; Shinde S; Grewal I; Henderson T; Flavell RA; Liu Y
Curr Biol; 1995 Nov; 5(11):1303-11. PubMed ID: 8574588
[TBL] [Abstract][Full Text] [Related]
20. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
